Copyright © DrugPatentWatch. Initially revealed at New patent for Emd Serono drug MAVENCLAD
Annual Drug Patent Expirations for MAVENCLAD
Mavenclad is a drug marketed by Emd Serono Inc and is included in a single NDA. It’s obtainable from one provider. There are 4 patents defending this drug.
This drug has 100 and fifteen patent relations in thirty-three nations.
The generic ingredient in MAVENCLAD is cladribine. One provider is listed for this compound. Further particulars can be found on the cladribine profile web page.
For extra data on how DrugPatentWatch may help together with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com
Make Higher Selections with DrugPatentWatch
Copyright © DrugPatentWatch. Initially revealed at New patent for Emd Serono drug MAVENCLAD
